Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Sees Large Decrease in Short Interest

by · The Markets Daily

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS – Get Free Report) was the target of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 34,897 shares, a decrease of 40.3% from the August 15th total of 58,435 shares. Based on an average trading volume of 13,850 shares, the days-to-cover ratio is currently 2.5 days. Approximately 0.8% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Cyclacel Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cyclacel Pharmaceuticals presently has an average rating of “Sell”.

View Our Latest Report on BGMS

Cyclacel Pharmaceuticals Trading Down 12.3%

Shares of BGMS stock traded down $0.13 on Wednesday, reaching $0.92. 21,021 shares of the company’s stock were exchanged, compared to its average volume of 885,222. Cyclacel Pharmaceuticals has a 52 week low of $0.57 and a 52 week high of $6.70. The stock has a market capitalization of $5.09 million, a PE ratio of -0.26 and a beta of -0.40. The company’s fifty day simple moving average is $0.90 and its 200 day simple moving average is $0.94.

Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.08) EPS for the quarter. Cyclacel Pharmaceuticals had a negative net margin of 118.27% and a negative return on equity of 31.60%. The business had revenue of $0.34 million during the quarter.

Cyclacel Pharmaceuticals Company Profile

(Get Free Report)

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.

Featured Stories